January 6, 2023
Life Sciences
  • AstraZeneca PLC and Sanofi SA said the Food and Drug Administration (FDA) indicated it may expedite the review of the companies’ long-acting antibody for the prevention of infection caused by RSV, called nirsevimab, with action possibly coming in the third quarter. Pediatric hospitals across the U.S. were strained late last year due to a surge of RSV cases. (Article here)